Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.14 USD
+0.03 (2.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.13 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LCTX 1.14 +0.03(2.70%)
Will LCTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for LCTX
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit